An Evaluation of the Cellular and Humoral Response of a Multi-Epitope Vaccine Candidate Against COVID-19 with Different Alum Adjuvants DOI Creative Commons

L Rojas,

Rocío Alejandra Ruiz‐Manzano,

Miguel Andrés Velasco-Elizondo

et al.

Pathogens, Journal Year: 2024, Volume and Issue: 13(12), P. 1081 - 1081

Published: Dec. 9, 2024

SARS-CoV-2 (Betacoronavirus pandemicum) is responsible for the disease identified by World Health Organization (WHO) as COVID-19. We designed “CHIVAX 2.1”, a multi-epitope vaccine, containing ten immunogenic peptides with conserved B-cell and T-cell epitopes in receceptor binding domain (RBD) sequences of different variants concern (VoCs). evaluated immune response mice immunized 20 or 60 µg chimeric protein two alum adjuvants (Alhydrogel® Adju-Phos®), plus PHAD®, two-immunization regimen (0 21 days). Serum samples were collected on days 0, 21, 31, 72 post first immunization, antibody titers determined indirect ELISA, while lymphoproliferation assays cytokine production flow cytometry. The presence neutralizing antibodies was assessed surrogate neutralization assays. Higher total IgG, IgG1, IgG2a antibodies, well increased proliferation rates specific CD4+ CD8+ T cells, observed μg Adju-Phos®/PHAD®. This formulation also generated highest levels TNF-α IFN-γ, addition to against Delta Omicron VoC. These findings indicate potential this vaccine combined promising platform viral infections, eliciting TH1 TH1:TH2 balanced cell response.

Language: Английский

Linking vaccine adjuvant mechanisms of action to function DOI
Elana Ben‐Akiva, Asheley P. Chapman, Tianyang Mao

et al.

Science Immunology, Journal Year: 2025, Volume and Issue: 10(104)

Published: Feb. 14, 2025

Vaccines deliver an immunogen in a manner designed to safely provoke immune response, leading the generation of memory T and B cells long-lived antibody-producing plasma cells. Adjuvants play critical role vaccines by controlling how system is exposed providing inflammatory cues that enable productive priming. However, mechanisms action underlying adjuvant function at molecular, cell, tissue levels are diverse often poorly understood. Here, we review current understanding adjuvants used subunit protein/polysaccharide mRNA vaccines, discuss where possible these link downstream effects on identify knowledge gaps will be important fill order continued development more effective for challenging pathogens such as HIV emerging threats.

Language: Английский

Citations

2
Supramolecular lipopeptidic adjuvant regulates protective abilities of MPXV subunit vaccine against monkeypox virus DOI

Wenxin Bao,

Yanwen Zhang, Chao Shang

et al.

Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: unknown, P. 160670 - 160670

Published: Feb. 1, 2025

Citations

0
The evolving role of B cells in malignancies DOI
Samik Bindu,

Roshni Bibi,

Roshini Pradeep

et al.

Human Immunology, Journal Year: 2025, Volume and Issue: 86(3), P. 111301 - 111301

Published: March 25, 2025

Language: Английский

Citations

0
Altered baseline immunological state and impaired immune response to SARS-CoV-2 mRNA vaccination in lung transplant recipients DOI Creative Commons
Mengyun Hu,

Ana Paula B N Oliveira,

Zhuoqing Fang

et al.

Cell Reports Medicine, Journal Year: 2025, Volume and Issue: unknown, P. 102050 - 102050

Published: April 1, 2025

The effectiveness of COVID-19 mRNA vaccines is diminished in organ transplant patients. Using a multi-omics approach, we investigate the immunological state lung (LTX) recipients at baseline and after SARS-CoV-2 vaccination compared to healthy controls (HCs). LTX patients exhibit immune profile resembling severe sepsis, characterized by elevated pro-inflammatory cytokines (e.g., EN-RAGE [also known as S100A12], interleukin [IL]-6), reduced human leukocyte antigen (HLA)-DR expression on monocytes dendritic cells, impaired cytokine production, increased plasma microbial products. Single-cell RNA sequencing identifies an enriched monocyte cluster marked high S100A family presentation genes. Post vaccination, show antibody, B cell, T cell responses, along with blunted innate signatures. Integrative analysis links these altered features vaccine responses. These findings provide critical insights into immunosuppressed condition their vaccine-induced adaptive

Language: Английский

Citations

0
Vaccination of a CdrA fragment conferred protection against Pseudomonas aeruginosa in wound infection via inhibition of biofilm formation DOI

Jiqing Wan,

Meilin Wu,

Zifan Zhu

et al.

Vaccine, Journal Year: 2025, Volume and Issue: 56, P. 127185 - 127185

Published: April 30, 2025

Language: Английский

Citations

0
Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants DOI Creative Commons
Holly A. Fryer, Daryl Geers, Lennert Gommers

et al.

Journal of Infection, Journal Year: 2024, Volume and Issue: 89(4), P. 106246 - 106246

Published: Aug. 8, 2024

Bivalent COVID-19 vaccines comprising ancestral Wuhan-Hu-1 (WH1) and the Omicron BA.1 or BA.5 subvariant elicit enhanced serum antibody responses to emerging subvariants. Here, we characterized RBD-specific memory B cell (Bmem) response following a fourth dose with bivalent vaccine, in direct comparison WH1 monovalent dose. Healthcare workers previously immunized mRNA adenoviral vector were sampled before one month after vaccine. Serum neutralizing antibodies (NAb) quantified, as well Bmem an in-depth spectral flow cytometry panel including recombinant RBD proteins of WH1, BA.1, BA.5, BQ.1.1, XBB.1.5 variants. Both elicited higher NAb titers against subvariants compared Following either vaccine type, recipients had slightly increased numbers. significantly binding all tested by cytometry, while recognition was not vaccination. IgG1

Language: Английский

Citations

2
Immunity by AS03ation: The natural adjuvantage DOI
Lena Hansen, Jenna J. Guthmiller

Immunity, Journal Year: 2024, Volume and Issue: 57(5), P. 927 - 929

Published: May 1, 2024

Language: Английский

Citations

0
Fluoroamphiphiles for enhancing immune response of subunit vaccine against SARS-CoV-2 DOI
Yuan Li,

Ziyao Kang,

Xuefeng Zhang

et al.

European Journal of Pharmaceutics and Biopharmaceutics, Journal Year: 2024, Volume and Issue: 204, P. 114528 - 114528

Published: Oct. 9, 2024

Language: Английский

Citations

0
Systems Vaccinology: Navigating the Future of Personalized Immunity and Next Generation Vaccines DOI Creative Commons

Serena Maria Dib,

S. Wimalasena, Daniel S. Graciaa

et al.

The Journal of Infectious Diseases, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 19, 2024

Systems vaccinology integrates a range of "omics" technologies to identify key immune signatures and enhance vaccine development. This approach aids in understanding variations responses, driven by genetics, health status, microbiome. Consequently, systems helps pave the way for personalized vaccination strategies, essential addressing diverse populations.

Language: Английский

Citations

0
Developing a universal multi-epitope protein vaccine candidate for enhanced borna virus pandemic preparedness DOI Creative Commons
Jingjing Zhang, Yongfeng Yang, Binyu Wang

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 5, 2024

Borna disease virus 1 (BoDV-1) is an emerging zoonotic RNA that can cause severe acute encephalitis with high mortality. Currently, there are no effective countermeasures, and the potential risk of a future outbreak requires urgent attention. To address this challenge, complete genome sequence BoDV-1 was utilized, immunoinformatics applied to identify antigenic peptides suitable for vaccine development.

Language: Английский

Citations

0